J Dig Cancer Res.
2022 Dec;10(2):74-81. 10.52927/jdcr.2022.10.2.74.
Recent Update on the Treatment of Colorectal Peritoneal Metastasis: A Surgical Perspective
- Affiliations
-
- 1Division of Coloproctology, Department of General Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea
- KMID: 2536424
- DOI: http://doi.org/10.52927/jdcr.2022.10.2.74
Abstract
- Colorectal peritoneal metastasis has been an incurable disease for centuries. However, since the new millennium, recent advancements in therapies are achieved with modern chemotherapeutic agents, target agents, and immune checkpoint blockade introduction. Modern chemotherapies, from a nearly nonexistent median survival if untreated, have raised the duration to 16 months with target agents. Experts have once again surpassed its limit by introducing intraperitoneal chemotherapy and cytoreductive surgery (CRS). Numerous clinical trials regarding CRS and hyperthermic intraperitoneal chemotherapy have now opened new doors in peritoneal carcinomatosis treatment, even securing complete remission. In addition, up-to-date modalities, such as pressurized intraperitoneal aerosol chemotherapy and immunotherapies, showed promising results at an early stage.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Treatment for Peritoneal Metastasis of Patients With Colorectal Cancer
- Risk Stratification of T1 Colorectal Cancer Metastasis to Lymph Nodes: Current Status and Perspective
- Advances in the Treatment of Colorectal Cancer with Peritoneal Metastases: A Focus on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
- Surgical treatment for metastatic colorectal cancer
- Update on Diagnosis and Treatment of Colorectal Cancer
